Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Kurmasheva RT, Bandyopadhyay A, Favours E, Del Pozo V, Ghilu S, Phelps DA, Erickson SW, Peer CJ, Figg WD, Smith MA, Houghton PJ. Kurmasheva RT, et al. Among authors: del pozo v. Pediatr Blood Cancer. 2019 Aug;66(8):e27820. doi: 10.1002/pbc.27820. Epub 2019 May 16. Pediatr Blood Cancer. 2019. PMID: 31099166 Free PMC article.
Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma.
Garcia N, Del Pozo V, Yohe ME, Goodwin CM, Shackleford TJ, Wang L, Baxi K, Chen Y, Rogojina AT, Zimmerman SM, Peer CJ, Figg WD, Ignatius MS, Wood KC, Houghton PJ, Vaseva AV. Garcia N, et al. Among authors: del pozo v. Mol Cancer Ther. 2022 Jan;21(1):170-183. doi: 10.1158/1535-7163.MCT-21-0194. Epub 2021 Nov 4. Mol Cancer Ther. 2022. PMID: 34737198 Free PMC article.
Moderate-High Blood Eosinophilia Is Associated with Increased Hospitalization and Other Asthma Comorbidities.
Naharro-González S, Lorente-Sorolla C, Rodrigo-Muñoz JM, Valverde-Monge M, Pinillos-Robles EJ, Betancor D, Fernández-Nieto M, Sánchez-Mellado D, Gil-Martínez M, Santillán-Coello JM, Villacampa-Aubá JM, Mahillo-Fernandez I, Herrero-González A, Perez-González A, Rodríguez-Nieto MJ, Del Pozo V. Naharro-González S, et al. Among authors: del pozo v. Biomolecules. 2024 Jan 18;14(1):126. doi: 10.3390/biom14010126. Biomolecules. 2024. PMID: 38254726 Free PMC article. Review.
Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases.
Del Pozo V, Bobolea I, Rial MJ, Espigol-Frigolé G, Solans Laqué R, Hernández-Rivas JM, Mora E, Crespo-Lessmann A, Izquierdo Alonso JL, Domínguez Sosa MS, Maza-Solano J, Atienza-Mateo B, Bañas-Conejero D, Moure AL, Rúa-Figueroa Í. Del Pozo V, et al. Front Immunol. 2024 Jan 5;14:1310211. doi: 10.3389/fimmu.2023.1310211. eCollection 2023. Front Immunol. 2024. PMID: 38250075 Free PMC article. Review.
Global Lung Initiative as diagnostic criteria in Asthma-COPD overlap syndrome. Prevalence and characterization of the syndrome in a real-life asthma cohort.
Betancor D, Otal M, Olaguibel JM, Rodrigo-Muñoz JM, Alvarez Puebla JM, Arismendi E, Barranco P, Barroso B, Bobolea I, Cárdaba B, Cruz MJ, Curto E, Del Pozo V, Domínguez-Ortega J, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Picado C, Plaza V, Quirce S, Rial MJ, Roibás-Veiga I, Soto-Retes L, Valero A, Valverde-Monge M, Sastre J. Betancor D, et al. Among authors: del pozo v. J Investig Allergol Clin Immunol. 2023 Dec 22:0. doi: 10.18176/jiaci.0966. Online ahead of print. J Investig Allergol Clin Immunol. 2023. PMID: 38131661 Free article. No abstract available.
Reply to "Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies".
Barroso B, Valverde-Monge M, Alobid I, Olaguibel JM, Rial MJ, Quirce S, Arismendi E, Barranco P, Betancor D, Bobolea I, Cárdaba B, Cruz Carmona MJ, Curto E, Domínguez-Ortega J, González-Barcala FJ, Martínez-Rivera C, Mahíllo-Fernández I, Muñoz X, Picado C, Plaza V, Rodrigo Muñoz JM, Soto-Retes L, Valero A, Del Pozo V, Mullol J, Sastre J. Barroso B, et al. Among authors: del pozo v. J Investig Allergol Clin Immunol. 2023 Dec;33(6):503-504. doi: 10.18176/jiaci.0953. J Investig Allergol Clin Immunol. 2023. PMID: 38095497 Free article. No abstract available.
Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
Valverde-Monge M, Sánchez-Carrasco P, Betancor D, Barroso B, Rodrigo-Muñoz JM, Mahillo-Fernández I, Arismendi E, Bobolea I, Cárdaba B, Cruz MJ, Del Pozo V, Domínguez-Ortega J, González-Barcala FJ, Olaguibel JM, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Peleteiro-Pedraza L, Picado Valles C, Plaza V, Quirce S, Rial MJ, Soto-Retes L, Valero A, Sastre J. Valverde-Monge M, et al. Among authors: del pozo v. Arch Bronconeumol. 2024 Jan;60(1):23-32. doi: 10.1016/j.arbres.2023.11.011. Epub 2023 Nov 22. Arch Bronconeumol. 2024. PMID: 38042707 English, Spanish.
Long-term immune response accompanies clinical outcomes in severe asthmatics treated with anti-IL-5/IL-5R biologics.
Lorente-Sorolla C, Bernaola J, Sánchez-Mellado D, Gil-Martínez M, Naharro-González S, Betancor D, Fernández-Nieto M, Pinillos-Robles EJ, Santillán Coello JM, Villacampa-Aubá JM, Rodríguez-Nieto MJ, Sastre J, Valverde-Monge M, Rodrigo-Muñoz JM, Del Pozo V. Lorente-Sorolla C, et al. Among authors: del pozo v. Allergy. 2023 Nov;78(11):3027-3031. doi: 10.1111/all.15872. Epub 2023 Aug 29. Allergy. 2023. PMID: 37643083 No abstract available.
158 results